Resolution of symptoms Not measured · patients with trigger finger
The review found no eligible studies for this question.
2 findings from 1 review
Pain (short‐term) Not measured · patients with trigger finger
The review found no eligible studies for this question.
2 findings from 1 review
Physical function · patients with trigger finger
2 findings from 1 review
Participant global assessment of success Not measured · patients with trigger finger
The review found no eligible studies for this question.
2 findings from 1 review
Recurrence ‐ not measured · patients with trigger finger
The review found no eligible studies for this question.
2 findings from 1 review
Adverse events Not measured · patients with trigger finger
The review found no eligible studies for this question.
2 findings from 1 review
Neurovascular injury Not measured · patients with trigger finger
The review found no eligible studies for this question.
2 findings from 1 review
Subjective well‐being · people with both severe mental illness and substance misuse
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Craving · people with both severe mental illness and substance misuse
1 finding from 1 review
Adherence to antipsychotic medication: number of missed doses, average endpoint data, short term (up to 6 months) · people with both severe mental illness and substance misuse
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse effects: Parkinsonism ‐ average endpoint score (SAS, high = worse) · people with both severe mental illness and substance misuse
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
It is very uncertain whether RISPERIDONE changes leaving study early: any reason compared with OLANZAPINE ‒ short‐ and long‐term data (very low certainty).
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
RISPERIDONE showed no clear difference in leaving the study early: any reason compared with PERHENAZINE ‒ long‐term data (low certainty).
1 finding from 1 review
Leaving the study early · people with both severe mental illness and substance misuse
RISPERIDONE showed no clear difference in leaving the study early: any reason compared with ZIPRASIDONE ‒ long‐term data (> 12 months) (low certainty).
1 finding from 1 review
Mental state: 2. Specific‐ Positive symptoms, total score‐ average endpoint scores (SADS‐C‐PD scale, lower = better) · people with both severe mental illness and substance misuse
1 finding from 1 review
Substance use: 1. Reduction of cannabis use‐change data (number of joints smoked/week) · people with both severe mental illness and substance misuse
1 finding from 1 review
Adverse events: hospital admission · people with pressure ulcers residing in long‐term‐care facilities
1 finding from 1 review
Adverse events: ED visits · people with pressure ulcers residing in long‐term‐care facilities
1 finding from 1 review
Proportion of participants developing a new pressure ulcer · people with pressure ulcers residing in long‐term‐care facilities
It is very uncertain whether enhanced multidisciplinary team (EMDT) changes pressure ulcer incidence rate compared with usual care (very low certainty).
1 finding from 1 review
Number of pressure ulcers healed · people with pressure ulcers residing in long‐term‐care facilities
It is very uncertain whether enhanced multidisciplinary team (EMDT) changes number of pressure ulcers healed compared with usual care (very low certainty).
1 finding from 1 review